Glucotrack (GCTK) Research & Development (2010 - 2026)

Glucotrack (GCTK) has reported Research & Development for 17 consecutive years, with $2.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Research & Development fell 36.0% year-over-year to $2.0 million; the trailing twelve-month figure through Jun 2026 stood at $10.0 million (up 13.38% YoY), and the FY2025 full-year result was $9.8 million, up 3.31% from the prior year.
• Research & Development grew to $2.0 million in Q2 2026 per GCTK's latest filing, from $1.6 million in the prior quarter.
• Across five years, Research & Development topped out at $3.6 million in Q2 2024 and bottomed at -$2.8 million in Q4 2023.
• Historically, Research & Development has averaged $1.4 million across 5 years, with a median of $1.7 million in 2023.
• The sharpest annual moves came in 2023 and 2024: Research & Development tumbled 568.71% in 2023, then jumped 472.41% in 2024.
• Over 5 years, Research & Development stood at $604000.0 in 2022, then sank by 568.71% to -$2.8 million in 2023, then soared by 160.01% to $1.7 million in 2024, then fell by 4.24% to $1.6 million in 2025, then grew by 23.91% to $2.0 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $2.0 million, $1.6 million, and $3.2 million for Q2 2026, Q4 2025, and Q3 2025 respectively.